Santhera launches DMD therapy in the UK following NICE nod
NICE’s positive final guidance for Agamree follows confirmation that no appeals were submitted against its positive December ...
pharmaphorum6d
Santhera preps UK Duchenne drug launch after NICE says yes
Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...
PMLiVE6d
Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC
Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium (SMC) to treat Duchenne ...
The Pharma Letter6d
Final NICE nod for Santhera’s Agamree
The UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends Agamree (vamorolone) for use in the National Health ...
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – ...
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
(SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently ...
Pharmabiz7d
Santhera gets positive recommendation from Scottish Medicines Consortium for use of Agamree to treat Duchenne muscular dystrophy
Santhera gets positive recommendation from Scottish Medicines Consortium for use of Agamree to treat Duchenne muscular dystrophy: Pratteln, Switzerland Wednesday, January 15, 2025 ...
Santhera Pharmaceuticals: Positive Developments and Market Expansion Justify Buy Rating with CHF25 Target
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Santhera Pharmaceuticals Holding (SPHDF – Research ...
Pharmabiz15d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
Taiwan News16d
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® ...
Nasdaq16d
Santhera And Clinigen Sign Agreement To Expand Access To AGAMREE For DMD Patients
(RTTNews) - Santhera Pharmaceuticals Holding AG (SANN.SW), a pharmaceutical company focused on rare neuromuscular diseases, announced on Monday, that it has entered into a Supply and Distribution ...